KEAP1 and lung carcinoma: This vulnerability makes KEAP1-mutant lung cancer cells or tumors sensitive to glucose transporter inhibition and suggests a potential therapeutic strategy to target disulfidptosis in this subset of lung cancers (Koppula et al., 2021a).